Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Drug resistance in castration-resistant prostate cancer and the therapeutic potential of mesoporous polydopamine-based nanoplatforms.

Created on 12 Nov 2026

Authors

Zemin Dou, Yongfang Xie, Shichao Yan, Xue Sun, Yangyang Han, Tingting Feng, Guohui Wang

Published in

Nanomedicine (London, England). Pages 1-15. Nov 12, 2026. Epub Nov 12, 2026.

Abstract

In castration-resistant prostate cancer (CRPC), the benefit of androgen receptor signaling inhibitors, taxanes, poly(ADP-ribose) polymerase (PARP) inhibitors, and immunotherapy is limited by systemic toxicity, molecular heterogeneity, biomarker-restricted efficacy, and prior therapy cross-resistance. These limitations undermine long-term disease control, particularly when tumoral drug distribution, intracellular retention, or multi-agent co-delivery is suboptimal. This review outlines major resistance mechanisms and their impact on current systemic regimens. It then introduces mesoporous polydopamine (MPDA) as a versatile nanoplatform with high drug-loading capacity, facile surface functionalization, photothermal responsiveness, and compatibility with combinatorial regimens. Reported PC-3 experiments include approximately 53% cell death with AS1411-targeted MPDA/docetaxel plus irradiation versus 25% without irradiation, and representative Annexin V/propidium iodide double-positive fractions of 85.9% with irradiated MPDA-mediated docetaxel/small interfering RNA co-delivery versus 39.5% with free docetaxel.

PMID:
43016294
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement